Home

Stock Ideas

Long Ideas

Healthcare

Summary

Boston Scientific remains a 'hold' as growth decelerates and competitive pressures intensify, particularly in Watchman and electrophysiology segments.

Management has shifted the growth focus to Interventional Cardiology, Endoscopy, and Neuromodulation, but meaningful improvements are not expected until 2028.

Recent product recalls, a cybersecurity incident, and repeated guidance cuts further cloud near-term visibility and risk further downward revisions.

Despite improved margins and a strong innovation pipeline, BSX's risk/reward profile is not compelling enough for a buy at current valuation.

Solskin/DigitalVision via Getty Images

Boston Scientific ( BSX ) is headquartered in Massachusetts and was founded in 1979. As a specialist in medical devices, their business is driven by two key segments: Cardiovascular and MedSurg.…